[Skip to content]

European Parkinson's Disease Association
Search our Site



Medication research papers

  • Brain Volume 139 Issue 4 Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's diseaseIn Parkinson's disease, reduced pupillary modulation by incentives was predictive of apathy severity, and independent of motor impairment and autonomic dysfunction as assessed using overnight heart rate variability measures. Reward sensitivity was further modulated by dopaminergic state, with blunted sensitivity when patients were OFF dopaminergic drugs, both in pupillary response and saccadic peak velocity response to reward. These findings suggest that reward insensitivity may be a contributory mechanism 24 July 2016
  • Movement Disorders Volume 31 Issue 6 Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's diseaseThis was the first study of a new sublingual apomorphine formulation in PD patients. In this open-label study, APL-130277 appeared to provide a convenient, rapid, and reliable method for treating OFF episodes. 19 July 2016
  • Movement Disorders Volume 31 Issue 6 Long-term effects of rasagiline and the natural history of treated Parkinson's diseaseThe ADAGIO Follow-Up study failed to demonstrate long-term benefits of early-start rasagiline treatment in the prior ADAGIO study. Clinically important milestones occurred in a substantial proportion of patients. 19 July 2016
  • Human Gene Therapy Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene TransferThese findings provide evidence for the long-term safety of neurturin when delivered to the putamen or the putamen-plus-substantia nigra via stereotactic surgery and rAAV2 gene transfer. They therefore supplement the safety results reported in four prior publications from the same subjects, significantly extending the safety data for gene therapy and neurotrophic factor expression targeting the brain and adding to growing evidence that rAAV vector-mediated gene therapy to the CNS can be administered safely. 18 July 2016
  • European Journal of Neurology Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysisIn this analysis of >750 patients with PD treated with rotigotine, the frequency of ICD behaviour AEs was 9.0%, with a specific incidence timeline observed. Active surveillance as duration of treatment increases may help early identification and management; once ICD behaviours are present rotigotine dose reduction may be considered. 18 July 2016
  • Movement Disorders Volume 31 Issue 7 Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 StudiesConclusions: Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment. 15 July 2016
  • npj Parkinson's Disease Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's diseaseOut of 354 enrolled patients, 286 had baseline and post-PEG-J assessments of resting tremors and were included in this analysis. At baseline the majority of patients (69%) had no resting tremors, whereas 13% had mild resting tremors, and 18% had significant resting tremors. A complete resolution in resting tremors after 12 months of LCIG treatment was reported for 78% and 70% of patients with mild and significant baseline resting tremors, respectively. Improvements in motor complications and quality of lif 14 July 2016
  • PlosONE Bee Venom for the Treatment of Parkinson Disease A Randomized Controlled Clinical TrialThis study did not evidence any clear symptomatic or disease-modifying effects of monthly bee venom injections over an 11 month period compared to placebo using a standard bee venom allergy desensitization protocol in Parkinson disease patients. However, bee venom administration appeared safe in non-allergic subjects. Thus, authors suggest that higher administration frequency and possibly higher individual doses of bee venom may reveal its potency in treating Parkinson disease. 12 July 2016
  • Journal of Parkinson's Disease Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodiesThis small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials. 11 July 2016
  • Planta Medica Medicinal Plants and Natural Products as Potential Sources for Antiparkinson DrugsIn this review, authors have compiled data on the principal medicinal plants and natural products as potential antiparkinsonian agents. They act by different mechanisms, such as the inhibition of α-synuclein condensation, reduction of oxidative stress and neuro-inflammation, increase of dopaminergic neurons survival, or the blockade of the A2 A receptor. 01 July 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]